相关实验视频
Updated: Jun 28, 2025

07:29
A Method for the Measurement of Salivary Gland Function in Mice
Published on: January 25, 2018
18.7K
吉米利普丁对唾液腺功能障碍的改善效果在外源性甲基醇注射的老鼠中
Woo Kwon Jung1, Su-Bin Park1, Hwa Young Yu1
1Department of Oral Pathology, School of Dentistry, Jeonbuk National University, Jeonju, 54896, South Korea.
Heliyon
|April 17, 2024
概括
杰米利普丁通过减少有害化合物和改善唾液产生来保护唾液腺免受糖尿病并发症的影响. 这种二二-4抑制剂为糖尿病唾液功能障碍提供了潜在的治疗方法.
科学领域:
- 内分泌学和新陈代谢学
- 口腔生物学 口腔生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病通常会导致唾液腺功能下降 (唾液下降).
- 甲基醇 (MGO) 和其衍生的高级糖化终产品 (AGEs) 导致糖尿病并发症.
- 唾液功能障碍增加了口腔感染和疾病的风险.
研究的目的:
- 调查吉米利普丁对MGO诱导的唾液腺功能障碍的保护作用.
- 评估吉米利普丁对MGO相关细胞损伤和唾液参数的影响.
主要方法:
- 试验室内:用MGO处理的人类唾液腺细胞评估了细胞亡和活性氧物种 (ROS).
- 在体内:大鼠接受MGO与gemigliptin或aminoguanidine两周.
- 评估的唾液体积,氨酶,DPP-4活性,AGE,AGE受体表达和水素5.
主要成果:
- 杰米利普丁通过ROS途径减轻了唾液腺细胞中MGO诱导的亡.
- 吉米利普丁增加了注射MGO的老鼠的唾液体积和氨酶.
- 吉米利普丁降低了DPP-4活性,AGE积累和AGE受体表达,同时增强了水素5.
结论:
- 杰米利普丁通过抗糖化和抗氧化作用保护唾液腺免受MGO诱导的损伤.
- 它改善唾液分泌和功能,表明它有可能作为糖尿病唾液功能障碍的治疗药物.
更多相关视频
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Salivary Glands and Saliva
664
The salivary glands, of which there are three pairs known as the parotid, submandibular, and sublingual glands, play a crucial role in maintaining oral health and initiating the digestive process. Positioned near the ears, beneath the masseter muscle, the parotid glands secrete saliva into the oral cavity through the parotid duct of Stensen. Meanwhile, the submandibular glands, located on the floor of the mouth, secrete saliva through channels named submandibular ducts. The sublingual glands,...
664
Oral Hypoglycemic Agents: Sulfonylureas
207
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
207

